Abstract: Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of use the bacterial minicells and pharmaceutical compositions.
Abstract: Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer.
Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
February 16, 2021
Assignee:
VAXIION THERAPEUTICS, LLC
Inventors:
Matthew J. Giacalone, Michael J. Newman
Abstract: Disclosed herein are methods of terminally sterilizing bacterial minicells or compositions comprising bacterial minicells by exposure to ionizing irradiation. Also disclosed are terminally sterilized bacterial minicells, pharmaceutical compositions comprising the bacterial minicells, and methods of use the bacterial minicells and pharmaceutical compositions.
Abstract: The present application relates to the use of bacterial minicells as targeted delivery agents in vivo and in vitro. Described herein are genetically engineered eubacterial minicells designed to preferentially target and deliver therapeutically relevant agents using a minicell surface coupling molecule capable of binding and displaying antibodies or other Fc-containing targeting moiety fusions and conjugates.
Type:
Grant
Filed:
February 15, 2012
Date of Patent:
June 26, 2018
Assignee:
VAXIION THERAPEUTICS, LLC
Inventors:
Matthew J. Giacalone, Michael J. Newman
Abstract: Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.
Type:
Grant
Filed:
April 22, 2015
Date of Patent:
June 6, 2017
Assignee:
Vaxiion Therapeutics, LLC
Inventors:
Roger Sabbadini, Neil Berkley, Mark Surber, Robert Klepper
Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.
Type:
Grant
Filed:
May 28, 2015
Date of Patent:
February 21, 2017
Assignee:
Vaxiion Therapeutics, LLC
Inventors:
Matthew J Giacalone, Stanley Maloy, Shingo Tsuji
Abstract: Embodiments of the present invention relates to the incorporation and use of a regulated genetic suicide mechanism for use in the improved purification of biologics, including adjunct use in various eubacterial minicell production and purification methodologies. Described herein are high-yield eubacterial minicell-producing strains with genetic modifications that comprise a regulated genetic suicide mechanism that irreparably destroys the parent cell chromosome such that live parental cells in a culture can be functionally eliminated at any time during the course of a minicell production and purification run. Embodiments of the present invention also describe methods useful in the elimination of live parental cells during the production of other cell-based biologics.
Type:
Grant
Filed:
December 11, 2012
Date of Patent:
June 2, 2015
Assignee:
Vaxiion Therapeutics, LLC
Inventors:
Matthew J Giacalone, Stanley Maloy, Shingo Tsuji